Karyopharm Therapeutics | Bienes

Assets Cambio Fecha
AbbVie USD 136.22B 854M 2023-09
Abbott USD 73.35B 440M 2023-06
Amgen USD 97.15B 6.62B 2023-12
AstraZeneca USD 96.09B 457M 2023-09
Avrobio USD 110.52M 23.31M 2023-09
BioCryst Pharmaceuticals USD 522.92M 6.96M 2023-09
Bristol-Myers Squibb USD 91.26B 2.23B 2023-09
Eli Lilly USD 57.92B 3.1B 2023-09
Enanta Pharmaceuticals USD 462.28M 32.89M 2023-09
GlaxoSmithKline GBP 60.86B 1.4B 2023-09
Incyte USD 6.78B 393.87M 2023-12
Merck USD 106.73B 2.26B 2023-09
Nektar Therapeutics USD 442.24M 52.04M 2023-09
Pfizer USD 215.02B 5.15B 2023-09
Regeneron Pharmaceuticals USD 33.08B 916.9M 2023-12
Roche Holding CHF 84.37B 3.78B 2023-06
Takeda JPY 14.87T 79.15B 2023-09
TG Therapeutics USD 329.59M 1.48M 2023-12
Ultragenyx Pharmaceutical USD 1.49B 252.87M 2023-12
Xencor USD 952.69M 174.26M 2023-12



Karyopharm Therapeutics Bienes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2024.